Cargando…

Tocilizumab: Herpes zoster infection following an off label use: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872904/ http://dx.doi.org/10.1007/s40278-022-10775-5

Ejemplares similares

Tocilizumab: Anaphylaxis following off-label use: case report
Publicado: (2021)

Tocilizumab: Neutropenia following off-label use: case report
Publicado: (2021)

Tocilizumab: Lack of efficacy following off-label use: case report
Publicado: (2022)

Tocilizumab: Septic shock following off-label use: case report
Publicado: (2020)

Tocilizumab: Lobar pneumonia following off label use: case report
Publicado: (2020)

Tocilizumab: Bacterial superinfection following off-label use: case report
Publicado: (2020)

Tocilizumab: Anastomotic leakage following off label use: case report
Publicado: (2021)

Tocilizumab: Active tuberculosis following off label use: case report
Publicado: (2021)

Tocilizumab: Cytomegalovirus colitis following off label use: case report
Publicado: (2021)

Tocilizumab: Off-label use and neutropenia: case report
Publicado: (2021)

Methylprednisolone/tocilizumab: Cytomegalovirus gastritis following off label use: case report
Publicado: (2022)

Tocilizumab: Various toxicities following an off-label use: 3 case reports
Publicado: (2020)

Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2020)

Tocilizumab: Decrease in WBC count following an off-label use: case report
Publicado: (2020)

Tocilizumab: Progression of multiple myeloma following off-label use: case report
Publicado: (2021)

Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2021)

Methylprednisolone/tocilizumab: Gastrointestinal perforation following off label use: case report
Publicado: (2021)

Tocilizumab: Bowel perforation following off-label use: 2 case reports
Publicado: (2021)

Tocilizumab: Various toxicities following off label use: 4 case reports
Publicado: (2021)

Tocilizumab: Candidaemia and Off-label-use: 3 case reports
Publicado: (2020)

Tocilizumab: Acute hypertriglyceridaemia and off-label use: case report
Publicado: (2020)

Tocilizumab: Off label use and lack of efficacy: case report
Publicado: (2021)

Tocilizumab: Invasive pulmonary aspergillosis following off-label use of tocilizumab for severe acute respiratory coronavirus-2 infection: case report
Publicado: (2021)

Dexamethasone/tocilizumab: Worsening of hepatitis E virus infection following off label use: case report
Publicado: (2022)

Methylprednisolone/tocilizumab: Fatal disseminated mucormycosis following off-label use: case report
Publicado: (2022)

Lopinavir/ritonavir/tocilizumab: Hypertriglyceridaemia following off-label use: 2 case reports
Publicado: (2020)

Chloroquine/tocilizumab: Leucopenia and liver injury following off-label use: case report
Publicado: (2020)

Tocilizumab: Intrauterine fetal demise following off-label treatment: case report
Publicado: (2022)

Dexamethasone/tocilizumab: Lack of efficacy following off-label therapy: case report
Publicado: (2022)

Dexamethasone/tocilizumab: Herpes virus reactivation and COVID-19-associated pulmonary Aspergillosis secondary to off label use: case report
Publicado: (2021)

Piperacillin/tazobactam/tocilizumab: Trichosporon asahii infection and off-label-use: case report
Publicado: (2021)

Remdesivir/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2022)

Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report
Publicado: (2020)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

Dexamethasone/tocilizumab: Off-label-use and lack of efficacy: case report
Publicado: (2021)

Dexamethasone/tocilizumab/tofacitinib: Lack of efficacy following off label use: 2 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Dexamethasone/methylprednisolone/tocilizumab: Fatal disseminated mucormycosis following off-label use: case report
Publicado: (2022)

Tocilizumab: Severe pocket inflammatory device reaction following off-label use: case report
Publicado: (2020)

Hydroxychloroquine/tocilizumab: Cytomegalovirus enterocolitis and hypovolaemic-shock following off-label use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hp21bd26v7p7fdh7vrh04ibter